A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jun 6, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment method for women with advanced breast cancer. Instead of the usual approach, which typically involves surgery first and then reconstruction later, this study will give participants radiation therapy before their mastectomy (surgery to remove the breast). After the mastectomy, the doctors will perform immediate reconstruction using tissue from another part of the patient’s body. The goal is to see if this method is safe and effective compared to the standard treatment.
To join the study, participants must be women aged 18 or older with a specific type of invasive breast cancer. They should have had a good response to initial treatments and be suitable candidates for the reconstruction. Participants can expect close monitoring throughout the trial to ensure their safety and to gather important information about how well this new approach works. It's important to note that certain conditions, like previous breast cancer or being pregnant, may prevent someone from participating in this study.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female sex, aged ≥18 years, with biopsy-proven invasive breast cancer
- • cT3-4 cN0-3 tumor
- • Partial or complete response to NAC on imaging and clinical examination using the Response Evaluation Criteria in Solid Tumors (RECISTv1.1) definition.
- • Desire to undergo autologous reconstruction and assessed to be an appropriate candidate by a plastic and reconstructive surgeon
- • Able to read and understand English
- Exclusion Criteria:
- • Prior ipsilateral breast cancer
- • Bilateral breast cancer
- • Pregnant
- • Stage IV disease at presentation
- • Stable disease or progressive disease after NAC
- • Surgically unresectable breast disease
- • BMI \>40
- • Prior history of thoracic radiotherapy
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Basking Ridge, New Jersey, United States
Middletown, New Jersey, United States
Montvale, New Jersey, United States
Harrison, New York, United States
Uniondale, New York, United States
Commack, New York, United States
Patients applied
Trial Officials
Audree Tadros, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials